It has also been shown to outperform PSP staging systems, including an MRI system sequencing the progression of brain atrophy across different regions and neuropathological systems reflecting the sequence of tau accumulation.20 This volume composite is currently the only neuroimaging measure to be used as the primary endpoint in a clinical trial.57 The gene discussed is MAPT; the disease is Brain atrophy.